ticagrelor + aspirin + BMS-986141

This is a fixed combination regimen of **ticagrelor** (a P2Y12 receptor antagonist), **aspirin** (an irreversible COX-1 inhibitor), and **BMS-986141**, an investigational, potent, orally bioavailable, highly selective, reversible small-molecule antagonist of **protease-activated receptor 4 (PAR4)**. The combination is under study for additive antithrombotic effects in patients with coronary artery disease and atherosclerotic cardiovascular disease, aiming to provide robust antiplatelet activity while minimizing bleeding risk. **Ticagrelor** works by inhibiting ADP-induced platelet aggregation through P2Y12 receptor blockade, **aspirin** irreversibly inhibits thromboxane A2 formation via COX-1, and **BMS-986141** blocks PAR4-mediated platelet activation and aggregation. The combination is intended for oral use, and preclinical/early clinical evidence supports its use to reduce thrombus formation in high shear stress conditions, possibly improving the benefit–risk ratio compared to standard dual antiplatelet therapy[1][2][4][7].